Using this knowledge-driven approach, the targeting of oncogenic alterations, such as the gene rearrangement BCR-ABL in chronic myelogenous leukemia (CML), ushered in the current era of “precision medicine” and “targeted therapy” [4]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.